Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)

About VarmX

Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio

News & events

All news
  • NewsScientific publications

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors

Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for...

  • Conferences & Events

New episode of The BioHub Podcast with VarmX’s COO Martijn Negen

Episode of The BioHub Podcast featuring our Chief Operating Officer Martijn Negen. In Q4 2025, VarmX signed a strategic collaboration...

All news